Clinical Trials List
2017-06-01 - 2026-08-31
Phase III
Terminated4
-
Trial Applicant
AbbVie
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/04/01
Investigators and Locations
Co-Principal Investigator
- Yi-Chang Liu Division of Hematology & Oncology
- Hui-Ching Wang Division of Hematology & Oncology
- 蔡郁棻 Division of Hematology & Oncology
- 許瑞峰 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- - - Division of Hematology & Oncology
- Tai-Chung Huang Division of Hematology & Oncology
- SHAN-CHI YU Division of Hematology & Oncology
- MING YAO Division of Hematology & Oncology
- Huai-Hsuan Huang Division of Hematology & Oncology
- Wen-Chien Chou Division of Others -
- CHENG-HONG TSAI Division of Hematology & Oncology
- Jih-Luh Tang Division of Hematology & Oncology
- Chieh-Lung Cheng Division of Hematology & Oncology
- - - Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Audit
None
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- Hui-Hua Hsiao 未分科
Audit
None
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
20 participants
-
Global
211 participants
